Navigation Links
Longer Lung Cancer Survival

According to the American Cancer Society, there are 172,000 Americans diagnosed with lung cancer each year. Because there are no early screening tests, many of these cancers are caught in their later stages, making them difficult to treat. A new drug is now helping patients who have failed standard treatment.
By going after that protein, the drug stops the cancer from growing. Studies show as many as 20 percent of patients //taking the drug actually had their tumors shrink by 50 percent or more. Another 35 percent had symptoms relieved.
Marcie has stage four lung cancer.Her first dose of chemotherapy didn’t work. More chemo and radiation followed, but her cancer didn’t go away. She says, "You want to hear words of encouragement and hope. You know, you just long for something."

Those words of hope came when she met Oncologist Karen Kelly, M.D., who introduced her to a promising drug called ZD-1839. ZD-1839, specifically targets a specific protein on a cancer cell,Says Dr. Kelly, of University of Colorado Health Sciences Center in Denver.

Dr. Kelly says, "It really provides them with a chance to have prolonged survival with a high quality of life. It’s not a magic bullet, but it really has helped a lot of patients with lung cancer."

Marcie takes the drug every day. She says, "This drug has given me renewed life and renewed hope and renewed faith. I live now with a love of life and enjoy every day and try not to take any day for granted." With more energy and more strength, she’s able to live life to the fullest.

On May 5, 2003, the FDA approved this drug for advanced stage lung cancer under the name Iressa. The major side effect of the drug is a mild skin rash, which can be treated with medication if needed. It is currently only offered to patients who have failed at least two different treatments of chemotherapy. The drug is given once a day in tablet form.

If you would like more information, plea se contact:

Tina Russell, R.N., OCM
Oncology Certified Nurse
University of Colorado Health Sciences Center
4200 East 9th Ave., B171
Denver, CO 80262
(720) 848-024

Related medicine news :

1. Longer airway in males increases sleep disorder risk
2. Patients Are Given Catheter Longer Than Necessary
3. Fat Patients Require Longer Needles
4. Patients In Ontario Wait Longer For Treatment
5. Quality Platelets and Improved Blood Availability No Longer a Pipe Dream
6. Oscar Winners Live Longer Than Co-Competitors
7. Threat from Chikungunya, No Longer a Fear
8. Cyber Sex, No Longer A Fantasy Of The Mind
9. Kids Face a Slim Chance of Growing Obese, If Breastfed Longer Than Three Months
10. Misleading Health Claims On Food Labels No Longer Allowed in EU
11. Slow Learners Have Longer Memories
Post Your Comments:

(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology: